Literature DB >> 9229034

Generalisability of results from randomised drug trials. A trial on antimanic treatment.

R W Licht1, G Gouliaev, P Vestergaard, M Frydenberg.   

Abstract

BACKGROUND: Exemplified by a randomised trial on antimanic treatment, this paper addresses the question of whether selection of patients for drug trials may limit the applicability of study results from the randomised patients to a wider population.
METHOD: During two-year period, all consecutively admitted patients from a defined catchment area were screened for inclusion criteria concerning age, diagnosis and severity of illness. The subsequently excluded subgroups of patients were compared with the randomised patients by multivariate data analysis.
RESULTS: One hundred and sixty-four patients met the inclusion criteria. However, after exclusion for various reasons, only 27 (17%) patients remained for randomisation. The randomised patients and the excluded patients differed substantially.
CONCLUSIONS: The generalisability of trial results is limited. Reports of randomised drug trials should carefully describe the screening procedure for inclusion and, when possible, present relevant comparisons-between the randomised patients and the various subgroups of excluded patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9229034     DOI: 10.1192/bjp.170.3.264

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

1.  Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network.

Authors:  Deborah A Zarin; Julia L Young; Joyce C West
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-01       Impact factor: 4.328

2.  The relevance to meta-analysis, systematic reviews and the cochrane collaboration to clinical psychiatry.

Authors:  P Tharyan
Journal:  Indian J Psychiatry       Date:  1998-04       Impact factor: 1.759

3.  Influence of sociodemographic and socioeconomic features on treatment outcome in RCTs versus daily psychiatric practice.

Authors:  R van der Lem; P M Stamsnieder; N J A van der Wee; T van Veen; F G Zitman
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-12-05       Impact factor: 4.328

4.  Comparison of clozapine response for inpatients in the research setting versus routine clinical practice.

Authors:  Douglas L Boggs; Deanna L Kelly; Raymond C Love; Robert P McMahon; Robert R Conley
Journal:  Psychiatr Q       Date:  2008-01-24

5.  The social, psychopathological and consumer context of rate of symptom improvement in acute mania.

Authors:  Jim van Os; Inge van Rossum; Maarten Boomsma; Eduard Vieta; Iris Goetz; Catherine Reed; Josep Maria Haro
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-27       Impact factor: 4.328

6.  Comparison of mania patients suitable for treatment trials versus clinical treatment.

Authors:  Alessandra Talamo; Ross J Baldessarini; Franca Centorrino
Journal:  Hum Psychopharmacol       Date:  2008-08       Impact factor: 1.672

Review 7.  Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

Authors:  Rayan K Al Jurdi; Alan Swann; Sanjay J Mathew
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

8.  How assess drugs in the treatment of acute bipolar mania?

Authors:  Michel Bourin; Florence Thibaut
Journal:  Front Pharmacol       Date:  2013-01-29       Impact factor: 5.810

Review 9.  Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.

Authors:  Gunn Elisabeth Vist; Dianne Bryant; Lyndsay Somerville; Trevor Birminghem; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS.

Authors:  N Bijker; J L Peterse; I S Fentiman; J-P Julien; A A M Hart; A Avril; L Cataliotti; E J T Rutgers
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.